Xarelto® is one of several new prescription blood thinning medications introduced in recent years as an alternative to Coumadin® (warfarin sodium) as it does not require routine blood monitoring during treatment. However, use of Xarelto® causes serious and uncontrolled internal bleeding, which results in life-threatening injuries or death. There is currently no anticoagulant solution to stop bleeding complications that may develop among users.
The Xarelto® Litigation Group was founded for members to exchange knowledge and information and to provide opportunities for informational meetings and education programs regarding the Xarelto® litigation. The Xarelto® Litigation Group will also offer assistance and guidance in regard to the coordination of a future MDL and state court litigations.
This Litigation Group was formed in July 2014.
The Xarelto® Litigation Group has a secure list server and a document library where members can share information, documents, and pertinent information as well as holds education programs.
AAJ Annual and Winter Conventions, or as needed by group members.